+91-8668442535
Home / Healthcare / Bacterial

Bacterial Pneumonia Market By Disease Type (Community-acquired Pneumonia, Healthcare-associated Pneumonia) By Drug Type (Antibiotics, Cough Medicine, Pain Killer/Fever Reducers, Vaccines) By Dosage Form (Oral, Intravenous) - Growth, Future Prospects & Competitive Analysis, 2016 – 2028

About this report

The global Bacterial Pneumonia Market report explores the critical analysis of the Bacterial Pneumonia industry using key parameters. The report consists of investment strategies, the need for investments in the Bacterial Pneumonia industry, and the multiple benefits for the investors. Importantly, this report sets out major changes in the global technical regulations for the Bacterial Pneumonia industry, as well as how economic and non-economic barriers are helping the Bacterial Pneumonia market grow. Moreover, the report analyzes the global, regional, and country-level historic and forecasted market size. The report also provides a comprehensive analysis of key investment propositions, demand and supply gap, competitors positioning, STAR analysis, SRC analysis, Tornado analysis. key technological developments, and other analyses such as porter's five forces analysis, PESTEL analysis, value chain analysis, etc.

bacterial-pneumonia-market

Key Highlights of the report

How are the major segments performing in the Bacterial Pneumonia Market?

In 2021, community-acquired pneumonia was the leading segment in the disease type. The expansion of the number of active clinical studies for the creation of therapeutic molecules greatly impacts how quickly the market develops. Merck and GSK are two businesses now investing much time and energy in research and development for pneumonia treatments.

In 2021, antibodies led the bacterial pneumonia industry, and this trend is anticipated to remain for the entire projection period. The introduction of generic medications to the market is responsible for this constant growth. Growing regulatory pressure on physicians in emerging nations to prescribe generics, recent patent expirations of branded pharmaceuticals, the affordability of generics, and recent patent expirations of branded drugs all increase growth possibilities. 

In 2021, drugs in dosage form will lead the market. Drug solubility and the degree of protein binding impact the strength of their effectiveness because of their varying penetration to various target locations of infection. 

Online pharmacies were the market segment with the highest CAGR during the projection period. Online pharmacies provide more affordable prices with lower transaction and product expenses than physical pharmacies. Online pharmacies also provide accessibility and convenience to those with limited mobility. These pharmacies also offer doorstep delivery promptly, which boosts customer preference. 

Which region dominated the Bacterial Pneumonia Market?

In 2021, North America was one of the major contributors to the global Bacterial Pneumonia market. Due to the increased prevalence of community-acquired pneumonia in the region, particularly in the U.S.is predicted to have a leading position in the global market for medications used to treat CABP. For instance, an article from the Asian Pacific Society of Respirology in 2017 states that while the overall incidence of community-acquired pneumonia in adults in the United States was around 2.5 per 1000 people, it increased to 6.3 and 16.4 per 1000 people in adults 65 and older and adults aged 79 and older, respectively.

What is the competitive environment of the Bacterial Pneumonia Market?

The competitive landscape of the Bacterial Pneumonia industry provides data on the overall economic profit made by vendors and businesses, the sales and revenues generated in this industry, the Bacterial Pneumonia market share globally, an overview of business organizations, the introduction of new products, and opportunities for the industrial Bacterial Pneumonia market. For instance, Zerbaxa was given FDA approval by Merck in June 2019. This medication is used to treat hospital-acquired bacterial pneumonia and pneumonia linked with ventilators. The firm's portfolio of pneumonia treatments was expanded by this method. On the other hand, Pfizer's 20-Valent Pneumococcal Conjugate Vaccine was given the breakthrough therapy designation by the U.S. FDA in September 2018. This vaccination is helpful in preventing invasive illness and pneumonia. This tactic improved the company's line of products.

Executive Summary

What is the opportunity in the Bacterial Pneumonia Industry Market?

Regarding market opportunity for pneumonia testing, there has been a change in consumer desire and a rise in the need for point-of-care diagnostic solutions over time. There is a critical need for quick diagnostic tools due to the increased prevalence of pneumonia. The point-of-care testing market has gained popularity among medical professionals and patients due to its major advantages, including convenience, quicker diagnosis, and better treatment outcomes. Rapid syndromic molecular assays for pneumonia give more diagnosis accuracy than the current gold standard of culture, according to an NCBI publication from January 2020. The research study contrasted a traditional diagnostic approach with the commercially available syndromic diagnostic testing Distribution channels, such as the Filmarray Pneumonia panel and Unyvero, and discovered that the first two items were more effective in detecting pneumonia. To combat the growing burden of the disease, major industry players are also aggressively creating point-of-care molecular diagnostics for early identification of pneumonia. For instance, the U.S. FDA approved the ImmuView S pneumoniae and L pneumophila Urinary Antigen Test in March 2020 for SSI Diagnostica A/S. It is a quick, lateral flow test recommended for finding antigens of Legionella pneumophila and Streptococcus pneumoniae in urine samples. 

Which are the major investments by the players in the Bacterial Pneumonia Industry Market?

Systems to prevent bacterial pneumonia have been employed in various industries because of their excellent adaptability and versatility. The main participant makes numerous investments; for instance, The Medicines Company received an initial grant from the Biomedical Advanced Research and Development Authority of USD 32 million in 2018, and it will receive an additional USD 100 million over five years to develop a portfolio of next-generation antibiotics that are expected to help in the fight against drug-resistant infections. 

Some of the major companies in the market are Pfizer, Inc., Eli Lilly and Company, Lupin Pharmaceuticals, Inc, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries, Ltd, Mylan N.V., Sanofi, AstraZeneca plc, GlaxoSmithKline plc, and Nabriva Therapeutics plc..

What are the Major Dynamics Factors for the Bacterial Pneumonia Market?

Due to the rise in bacterial resistance, antibiotics are losing their ability to treat bacterial pneumonia. New antibiotic prospects are the subject of ongoing innovation in the pharmaceutical sector. This is anticipated to accelerate the rate at which bacterial pneumonia is cured shortly. In addition, rising rates of community-acquired pneumonia, particularly in younger people, are a major driver of market expansion. According to the WHO, children in underdeveloped nations account for 95% of all pneumococcal episodes.

What are the Major Risks for the Bacterial Pneumonia Market?

Over time, regulatory authorities' processes for approving medications for bacterial pneumonia have become more complicated, impractical, and possibly irrelevant to patients and clinicians. Additionally, the cost and duration of drug development are greatly increased by scientific and regulatory hurdles, which exacerbates the financial disadvantages of bacterial pneumonia medications. Regulatory authorities do not support the revision and streamlining of the anti-bacterial drug research and licensing process due to the urgency of bacterial drug resistance and the potential for targeted diseases to evolve significantly over time.

Which is the key Drug Type in the Bacterial Pneumonia Market?

The antibodies sector dominated the bacterial pneumonia market in 2021. A special kind of antibody is used to treat bacterial pneumonia. A class of antibiotics known as aminopenicillin is typically used to treat upper and lower respiratory tract infections. According to the Infectious Disease Society of America, the first-line treatment for community-acquired pneumonia is the penicillin-like medication amoxicillin. When amoxicillin binds to penicillin-binding proteins, an autolytic enzyme is activated, which breaks down the bacterial cell wall and kills the bacterial cell. According to a 2017 study published in the Journal of Infection, the number of hospital stays is larger in the case of adults, putting them at a higher risk of developing hospital-acquired pneumonia. Additionally, according to a 2017 study in Age and Ageing, 1.5% of persons have pneumonia that they contracted while in the hospital. Thus, the market in this sector is anticipated to be driven by the rising prevalence of pneumonia in the geriatric population and the development of products.

How is the Bacterial Pneumonia Market performing in regions?

In 2021, the global bacterial pneumonia market was dominated by North America. Because of the rising number of product approvals and the burden of pneumonia infection. Over 250,000 people in the United States receive treatment for pneumonia each year, and 50,000 people pass away as a result, according to the Centers for Disease Control and Prevention. Additionally, the US FDA approved Xenleta by Nabriva Therapeutics plc in 2019 to treat people with community-acquired pneumonia infection. Thus, it is anticipated that these variables will benefit the market for pneumonia treatments. Over 900,000 Americans contract the streptococcus pneumoniae virus each year, according to the American Lung Association. This highlights the necessity for the creation of advanced generation treatments and can be ascribed to the growing elderly population and the rise in adult and paediatric multidrug resistance. As a result, players in the global market are increasing their R&D spending and concentrating on new product development efforts.

Additionally, numerous government programs for diagnosing, treating, and preventing pneumonia have had a favorable effect across North America. For instance, UNICEF and WHO's Integrated Global Action Plan for Pneumonia and Diarrhea aims to reduce child fatalities from diarrhea and pneumonia that could have been prevented. This project is concentrated on treatments and services that promote access to treatment and preventive measures while increasing awareness.

What is the regulatory landscape for the Bacterial Pneumonia Market?

Governments are examining the regulatory environment for this market as they consider a more stringent regulatory approach regionally. The FDA, PMDA, and EMA concluded in 2016 that a more structured and in-depth conversation and in-person meetings were necessary to clarify the differences and consider solutions.

What is the Market Size of Bacterial Pneumonia regarding value?

In the future, the global market for bacterial pneumonia will be expected to expand at a sizable CAGR of XX%. By 2028, the market for bacterial pneumonia was predicted to be worth USD XX billion, up from USD XX billion in 2021.

What are key players planning for the future of the Bacterial Pneumonia Market?

Due to several national and international competitors, the competitive landscape of the worldwide market is fragmented. To increase market revenue, however, prominent industry competitors have relied on techniques including product launches and a concentration on mergers and acquisitions. 

Segmentation of Global Bacterial Pneumonia Market-

Global Bacterial Pneumonia Market – By Disease Type

  • Community-acquired Pneumonia
  • Healthcare-associated Pneumonia

Global Bacterial Pneumonia Market – By Drug Type

  • Antibiotics
  • Cough Medicine
  • Pain Killer/Fever Reducers
  • Vaccines

Global Bacterial Pneumonia Market – By Dosage Form

  • Oral
  • Intravenous

Global Bacterial Pneumonia Market – By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Bacterial Pneumonia Market – By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Frequently asked questions about the Bacterial Pneumonia

The coronavirus pandemic has also impeded the development, manufacture, and distribution of medications and other healthcare products, as well as the growth of the healthcare sectors of many businesses globally.

North America held the largest market share for Bacterial Pneumonia.

Antibiotics are becoming less effective at treating bacterial pneumonia due to the rise in bacterial resistance. Pharmaceutical industry innovation is constantly focused on developing new kinds of antibiotics. These are the driving factor for this market.

Community-acquired Pneumonia segment had a major share in 2021.

Antibodies segment had a major share in the global market in 2021.

Bacterial Pneumonia Market Scope

Report Attribute Details
Market Value in 2021 USD XX billion
Market Value in 2028 USD XX billion
CAGR XX%
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Trusted By
Godaddy
Published Date:  Sep 2022
Category:  Healthcare
Report ID:   60680
Report Format:   PDF
Pages:   120
Rating:    4.6 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support